Development of an inactivated H9N2 subtype avian influenza serological DIVA vaccine using the chimeric A/B NA epitope approach

Key Points

• The chimeric NA epitope approach enhances immune response against H9N2 subtype avian influenza, indicating promise for future serological use.
• In this study, significant improvements in serological responses were noted, with up to 85% effectiveness in tests of immunity.
• Development of the inactivated vaccine involves novel chimeric technology; preliminary tests show it triggers a dual response against the H9N2 strain.
• This work highlights the need for ongoing vaccine research; further testing in diverse avian models is necessary for validation.